RESUMEN
BACKGROUND: Acne vulgaris (AV) is an inflammatory skin disease of the pilosebaceous unit. S100A8 and S100A9 (the light subunits of calprotectin) gene polymorphisms have been known to be associated with inflammatory disorder. Until now, no study investigated calprotectin gene polymorphism in acne patients. OBJECTIVE: This study was designed to investigate calprotectin serum levels and gene polymorphism (rs3806232) in acne vulgaris patients and to correlate them with different clinical aspects of them. METHODS: This case-control study included 50 patients having variable degrees of acne vulgaris (AV) severity, in addition to a control group of 26 age- and gender-matched seemingly healthy volunteers. RESULTS: Acne vulgaris patients had considerably greater (P < 0.001) mean serum calprotectin levels than the control group (3.86 ± 2.58 pg/ml vs. 0.29 ± 0.14). AA genotype of calprotectin S100 A8 (rs3806232) was significantly predominant over AG or GG genotypes in patients compared to the controls, and the A allele was significantly (P < 0.001) predominant in patients (80%), while A and G alleles were equally distributed in controls; also, there was a significantly higher serum calprotectin level in calprotectin AA genotype than in AG or GG (P < 0.001) in acne vulgaris patients. CONCLUSION: The serum levels of calprotectin were considerably greater in AV patients than in controls. AA genotype and A allele of the S100 A8 gene were significantly higher in patients, which was associated with significantly higher calprotectin serum levels. Thus, calprotectin, both gene and serum level, might participate in disease pathogenesis, which needs further studies.